KEYMED BIO-B (02162) opened over 4% higher, rising 4.23% to HK$61.6 by the time of writing, with a turnover of HK$1.3244 million.

On December 7, KEYMED BIO announced that its self-developed Class 1 innovative drug Kangyueda® (Sprifermin Injection) has been included in the National Reimbursement Drug List (NRDL) for 2025, which will take effect on January 1, 2026.

Kangyueda® (Sprifermin) is the first domestically developed and approved IL-4Rα humanized monoclonal antibody in China. It precisely inhibits type 2 inflammatory diseases by dual-blocking the IL-4/IL-13 signaling pathway.

Currently, Kangyueda® (Sprifermin) has been approved for three indications: moderate-to-severe atopic dermatitis in adults inadequately controlled by topical treatments, chronic rhinosinusitis with nasal polyps inadequately controlled by corticosteroids and/or surgery, and moderate-to-severe seasonal allergic rhinitis in adults inadequately controlled by nasal corticosteroids and antihistamines. All three indications have been included in the updated NRDL.